# Autologous OC-L Vaccine and Ovarian Cancer

> **NCT02452775** · PHASE1 · TERMINATED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 3 (actual)

## Conditions studied

- Primary Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer

## Interventions

- **BIOLOGICAL:** OC-L
- **OTHER:** Montanide
- **OTHER:** poly-ICLC (Hiltonol),

## Key facts

- **NCT ID:** NCT02452775
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05
- **Primary completion:** 2018-05-30
- **Final completion:** 2018-05-30
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2020-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02452775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02452775, "Autologous OC-L Vaccine and Ovarian Cancer". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT02452775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*